XORTX Therapeutics Inc. issued a press release in error today, re-issuing a previous release from April 17, 2025. The company received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share. If the bid price is at least $1 per share for 10 consecutive business days by April 13, 2026, compliance will be achieved. Failure to meet this requirement may result in delisting from Nasdaq. The company is also listed on the TSX Venture Exchange, with compliance status unaffected by Nasdaq’s notification. XORTX is evaluating options to resolve the deficiency and regain compliance.

Read more at GlobeNewswire: XORTX Issues Correction Notice and XORTX Announces 180-Day